What is the difference between Pramlintide and Retatrutide?

Pramlintide: Synthetic amylin analogue; activates amylin receptors in hypothalamus; slows gastric emptying, suppresses glucagon, enhances satiety Retatrutide: Triple GIP/GLP-1/glucagon receptor agonist; targets three pathways for synergistic fat reduction

Is Pramlintide FDA approved?

Pramlintide is FDA approved (FDA status current as of 2005-03-16). This regulatory status is provided for research and educational context only.

How is Pramlintide administered in research settings?

In research settings, Pramlintide is typically administered via the subcutaneous route. PeptideBase does not provide dosing or administration instructions.

How is Retatrutide administered in research settings?

In research settings, Retatrutide is typically administered via the subcutaneous route. PeptideBase does not provide dosing or administration instructions.

Home›Research›Compare›Pramlintide vs Retatrutide

Peptide Comparison

Pramlintide vs Retatrutide

Name: Pramlintide vs Retatrutide — Per-mg Price Comparison
Creator: PeptideBase
License: https://peptidebase.io/terms

Both are Metabolic peptides.

Pramlintide

Symlin

Fat LossFDA ApprovedPrescription

Half-life: ~48 minutes

No providers listed yet

Full Pramlintide profile →

Retatrutide

GLP-3

Fat LossUnder clinical reviewResearch Only

Half-life: ~6 days

96 providers listed

Full Retatrutide profile →

Bottom line

Pramlintide is FDA-approved, while Retatrutide is investigational — the clearest structural difference between them.

Quick Verdict

Pramlintide

Half-life

~48 minutes

Retatrutide

Half-life

~6 days

Which One Should You Choose?

Your goal	Better option
Stronger clinical evidence	Retatrutide
Further along in FDA review	Pramlintide
Less frequent dosing (longer half-life)	Retatrutide
More provider options (0 vs 96)	Retatrutide

Research summary only — not medical advice. Consult a qualified provider before making any decisions.

Side-by-Side Comparison

Pramlintide

Retatrutide

Mechanism Family

Metabolic

Half-life

~48 minutes

~6 days

FDA Status

approved

Under clinical review

Admin Routes

subcutaneous

Availability

Prescription

Research Only

Providers

None listed

96 listed

FDA Update

Mar 2005

Under clinical review

Avail. Notes

FDA-approved amylin analog. Brand: Symlin (NDA 021332, Mar 2005). Adjunct to insulin therapy in T1D and T2D. Prescription only. Subcutaneous injection.

Triple GIP/GLP-1/glucagon agonist by Eli Lilly. Pivotal Phase 3 readouts across obesity (TRIUMPH-1, May 2026), obesity + knee osteoarthritis (TRIUMPH-4, Dec 2025), type 2 diabetes (TRANSCEND-T2D-1, Mar 2026), obesity + type 2 diabetes (TRIUMPH-2, Jul 2026), and severe obesity + cardiovascular disease (TRIUMPH-3, Jul 2026); OSA trial in program. Not FDA-approved; Lilly plans to submit a Biologics License Application (BLA) to FDA in Q1 2027. NCT05929066.

Research Evidence

Pramlintide

RCT · 3 key studies · most recent 2026

Retatrutide

Meta-analysis · 10 key studies · most recent 2026

Research Citations

Pramlintide

RCT2009 · Obesity

Pramlintide combined with metreleptin in obesity: sustained reductions in weight, metabolic markers, and lept…

RCT2007 · American Journal of Physiology: Endocrinology and Metabolism

Pramlintide reduced 24-h caloric intake and increased satiety in obese subjects: a randomized, double-blind,…

In vitro2026 · J Pharm Biomed Anal

In vitro metabolic profiling of weight-loss-inducing amylin receptor agonists in the context of preventive do…

Retatrutide

Meta-analysis2026 · Ann Intern Med

Benefits and Harms of Pharmacologic Treatments in Adults With Overweight or Obesity: A Living Systematic Revi…

RCT2026 · J Clin Endocrinol Metab

Retatrutide And Lipid And Metabolite Profiles In Participants With Obesity With Or Without Type 2 Diabetes.

RCT2025 · Diabetes, Obesity and Metabolism

Design of the TRIUMPH phase 3 clinical trial programme for retatrutide in obesity and cardiometabolic disease

RCT2023 · New England Journal of Medicine

Triple-hormone-receptor agonist retatrutide for obesity — a phase 2 trial

+6 more

About Pramlintide

Synthetic amylin analogue; activates amylin receptors in hypothalamus; slows gastric emptying, suppresses glucagon, enhances satiety

Research Areas

appetite suppressionpostprandial glucose controlweight lossgastric emptying delay

About Retatrutide

Triple GIP/GLP-1/glucagon receptor agonist; targets three pathways for synergistic fat reduction

Research Areas

profound weight lossappetite suppressionmetabolic improvement

Safety Profile

Information below reflects published research data only — not medical advice. Consult a qualified provider before use.

Pramlintide

Reported (Unverified — Pending Clinical Review)

hypoglycemia unawarenessgastroparesis

No established clinical contraindications

Suggested Monitoring

Under clinical review

Being verified by our medical team before we display monitoring guidance for this peptide.

Retatrutide

Absolute Contraindications

Personal or family history of medullary thyroid carcinoma (MTC)Multiple Endocrine Neoplasia syndrome type 2 (MEN 2)Known hypersensitivity to the drug or excipients

Warnings & Cautions

Acute pancreatitisPregnancy (discontinue; not for use in pregnancy)Gallbladder disease / cholelithiasisDiabetic retinopathy complications (reported with GLP-1 receptor agonist use)Severe GI disease / gastroparesis / ileus riskHypoglycemia when combined with insulin or sulfonylureasAcute kidney injury secondary to volume depletion

Class-based (investigational)

Price (per mg)

Pramlintide

Not enough vendor pricing yet.

Retatrutide

$9.14/mg

$8.50 – $11.45 range

12 vendors

View price index →Find providers →

Find Providers

Where to source these peptides

Providers offering

Pramlintide

Browse directory →

Providers offering

Retatrutide

96 listed

Browse directory →

PeptideBase lists providers for educational research purposes only. Always consult a qualified healthcare professional before obtaining or using any peptide.

More Metabolic Comparisons

Browse all peptides →

Educational research tools — not medical advice.

Cite this page

Data last updated August 26, 2026

Free to reference and republish with attribution to PeptideBase. Choose a format:

PeptideBase. (2026). Pramlintide vs Retatrutide — Per-mg Price Comparison. Retrieved September 11, 2026, from https://peptidebase.io/peptides/compare/pramlintide/retatrutide

https://peptidebase.io/peptides/compare/pramlintide/retatrutide Methodology License Download JSON Download CSV